OMGEN was created to provide expertise to rare disease / specialty care companies to address the barriers to bringing innovation to patients in the rare and gene therapy space. please get in touch if you would like an exploratory discussion to see how we can help. We focus on:

Strategy: rare disease commercial excellence, Marketing strategy, market access and launch planning and execution

Consulting: improving customer experience in rare disease, patient-centred planning, vision and purpose

Change: team building, Management and leadership, Diversity Equity and Inclusion and Esg programmes

Prior to setting-up OMGEN, Owen served as Business Unit Head of Rare Diseases for Pfizer in the UK. His portfolio encompassed cutting-edge therapies, including Gene Therapies, treating rare disorders like Rare Cardiology, Endocrine, Neuro Muscular, Neuropathies and Haematology conditions. Successfully securing reimbursement through various mechanisms, engaging with NICE, NHS England, NHS Scotland and DHSC (Department of Health and Social Care).

A graduate in Biological Sciences from the University of Edinburgh, Owen commenced his career in Sales, before a move into Marketing in Cardiovascular, Mental Health therapy areas. His career trajectory extends across Europe and International Developed Markets, where he held prominent positions in global and regional marketing leadership. Based in France and then Italy, Owen led teams responsible for Haemophilia and Rare and Orphan Medicines across Western, Central, and Eastern Europe.

Owen’s expertise in organisational planning and change leadership shines through his leadership roles in major transitions within the pharmaceutical industry. He played a pivotal role in the transition into Pfizer of Global Blood Therapeutics, consolidating the UK HIV business into ViiV Healthcare and led the planning council for the Pfizer: Wyeth merger in the UK.

Owen’s dedication to diversity, equity, and inclusion (DEI) is evident through his co-chairmanship of the Pfizer UK Diversity, Equity, and Inclusion Group. Under his leadership, Pfizer UK achieved a perfect score in DEI practices, as assessed by Top Employer. Notably, Pfizer’s commitment to DEI earned accolades such as winning Gold in the annual award from the Employers Network for Equality and Inclusion (enei) for its Gender Pay Gap action plan.

Beyond his corporate responsibilities, Owen held esteemed positions within various influential organisations. He chaired the Advanced Therapeutic Medicines Group for the ABPI and the South East Board for Business in the Community (BITC). Additionally, he actively contributed to the BIA Rare Disease Industry Group and served as a Mentor for the Social Mobility Foundation (SMF) and society for social entrepreneurs (SSE).

Through his multifaceted expertise and commitment to excellence, Owen Marks continues to leave an indelible mark on the rare disease, pharmaceutical commercial and consulting landscape. OMGEN are committed to enabling you to deliver your priorities.